Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).
Muscular Invasive Bladder Cancer (MIBC)
DRUG: SHR-A2102；Adebrelimab
Phase II: pCR evaluated by researchers;, Three months after the last subject underwent RC+PLD surgery|Phase III: EFS assessed by BICR；, 5 years after the first medication of the last subject
ORR, from first dose to disease progression or death, whichever comes first, up to 3 years|DCR, from first dose to disease progression or death, whichever comes first, up to 3 years|pCR, Three months after MIBC surgery|EFS, from first dose to disease progression or death, whichever comes first, up to 3 years|DFS, from first dose to disease progression or death, whichever comes first, up to 3 years|OS, from first dose to disease progression or death, whichever comes first, up to 3 years|R0 resection rate, One month after the last subject underwent RC+PLD surgery|AE, from Day1 to 90 days after last dose
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).